Evaluation of survival outcomes and prognostic factors of carcinoma anal canal at a tertiary cancer center

• Published in: Journal of cancer research and therapeutics Vol. 19; no. 7; pp. 1998 - 2004
• Main Authors: Mishra, Himanshu, Mishra, Ritusha, Singh, Ankita, Mandal, Abhijit, Singh, Tej B, Asthana, Anupam K
• Format: Journal Article
• Language: English
• Published: India Medknow Publications and Media Pvt. Ltd 01.10.2023; Medknow Publications & Media Pvt. Ltd
• Subjects: Anal Canal; Anal cancer; Anus; Cancer; Carcinoma, Squamous Cell - therapy; Care and treatment; Chemotherapy; Disease-Free Survival; Humans; Medical prognosis; Middle Aged; Patient outcomes; Prognosis; Progression-Free Survival; Radiotherapy; Squamous cell carcinoma; India
• ISSN: 0973-1482; 1998-4138
• DOI: 10.4103/jcrt.jcrt_357_22

Concurrent chemoradiotherapy is considered a standard of care for patients with carcinoma anal canal. Being an unusual malignancy, there is limited Indian data regarding survival outcomes and prognostic factors. To evaluate survival outcomes and associated prognostic factors in patients with carcinoma anal canal treated with radical intent. Patients with squamous cell carcinoma of the anal canal, treated with radical intent between 2015 and 2019 were included in the study. Data regarding the baseline characteristics of the patients and treatment outcomes were collected and analyzed. Survival rates were estimated using Kaplan-Meier method. To determine survival difference between the groups, log-rank test was used. Multivariate analyses were performed with Cox proportional hazard models and P value < 0.05 was considered significant. Forty-two patients were identified after applying suitable eligibility criteria. The median age was 55 years (range: 26-80 years).The median follow-up duration was 23.5 months (range: 1.9-51.9 months). The 3-year overall survival (OS), disease-free survival (DFS), and locoregional (LRC) were 78.5%, 53.1%, and 66.4%, respectively. On multivariate analysis, inferior DFS was significantly affected by lack of concurrent chemotherapy (CT) (hazard ratio [HR], 11.50; 95% confidence interval [CI], 1.92-68.78; P = 0.007) and radiotherapy (RT) dose of 45 Gy or less (HR, 35.96; 95% CI, 6.32-204.56; P = 0.000). For patients of carcinoma anal canal, concurrent CT and RT dose are independent prognostic factors influencing DFS.